Authors:
György Paragh Medical and Health Science Center, University of Debrecen 1st Department of Medicine Debrecen Hungary

Search for other papers by György Paragh in
Current site
Google Scholar
PubMed
Close
,
Gyula Pados Szent Imre Hospital, 4th Department of Medicine Independent Department of Lipidology Budapest Hungary

Search for other papers by Gyula Pados in
Current site
Google Scholar
PubMed
Close
,
László Márk Pándy Kálmán Békés County Hospital Semmelweis u. 1 H-5700 Gyula Hungary

Search for other papers by László Márk in
Current site
Google Scholar
PubMed
Close
,
István Karádi Semmelweis University 3rd Department of Medicine Budapest Hungary

Search for other papers by István Karádi in
Current site
Google Scholar
PubMed
Close
,
Mária Audikovszky Szent Imre Hospital, 4th Department of Medicine Independent Department of Lipidology Budapest Hungary

Search for other papers by Mária Audikovszky in
Current site
Google Scholar
PubMed
Close
,
Károly Zámolyi Bajcsy-Zsilinszky Hospital Department of Cardiology Budapest Hungary

Search for other papers by Károly Zámolyi in
Current site
Google Scholar
PubMed
Close
, and
László Romics Semmelweis University 3rd Department of Medicine Budapest Hungary

Search for other papers by László Romics in
Current site
Google Scholar
PubMed
Close
Restricted access

Purpose: Improving the management of cardiovascular disease in Hungary represents an important clinical challenge. This article assesses the achievement of national consensus total cholesterol goals among Hungarian patients of physicians educated about the consensus guidelines and assisted in cardiovascular risk assessment. Methods and results: A total of 320 general practitioners provided data on 15,404 eligible patients. Among these individuals, 14,018 (91%) had documented atherosclerosis and the remaining 9% had ≥ 2 risk factors. Despite this, less than half of all patients received lipid-lowering therapy. Only 12% of high-risk patients attained the consensus total cholesterol target of < 4.5 mmol/L (< 175 mg/dL) and 31% of individuals at low-moderate risk achieved the consensus goal of < 5.0 mmol/L (< 194 mg/dL) at the first visit. Among patients in the high-risk group whose total cholesterol levels were above the consensus goal at the first visit, 54% received no lipid-lowering therapy and 46% received inadequate treatment. Overall, lipid-lowering treatment was considered inadequate in most (77%) patients. Dose adjustments and other regimen changes after the first visit were infrequent. Conclusion: Most Hungarian patients seen in primary-care practices did not achieve consensus cholesterol goals. Improvements in lipid-lowering therapies and strategies, as well as enhanced patient education to promote adherence to lifestyle and medication regimens, may be needed to improve cholesterol goal attainment in Hungary. Potential limitations of the study included selection bias and the use of a convenience sample to recruit physicians.

  • Petersen, S., Peto, V., Rayner, M. et al.: European cardiovascular disease statistics. 2005 edition. Available at: http://www.ehnheart.org/cms/site/showdoc.asp?id=5883 . Cited 23 May 2007

  • World Health Organization: Atlas of heart disease and stroke: types of cardiovascular disease 2005. Available at: www.who.int . Cited 10 April 2007

  • European Heart Network: CVD statistics: statistical data about cardiovascular disease in Europe. Available at: http://www.ehnheart.org/content/sectionintro.asp?level0=1457 . Cited 23 May 2007

  • Keltai, M., Márkus, R., Sitkei, E. et al.: Comparison of invasive diagnostic techniques and revascularization therapy of acute coronary syndrome in Hungarian and international databases. (In Hungarian). Orv. Hetil., 2002, 143 , 117–122.

    Sitkei E. , 'Comparison of invasive diagnostic techniques and revascularization therapy of acute coronary syndrome in Hungarian and international databases (In Hungarian) ' (2002 ) 143 Orv. Hetil. : 117 -122 .

    • Search Google Scholar
  • Szucs, T. D.: Healing unhealthy Hungarian hearts – at what cost? – with what benefit?. Cardiovasc. Drugs Ther., 2006, 20 , 239–243.

    Szucs T. D. , 'Healing unhealthy Hungarian hearts – at what cost? – with what benefit? ' (2006 ) 20 Cardiovasc. Drugs Ther. : 239 -243 .

    • Search Google Scholar
  • Vargáné, H. P., Ádány, R.: Trends of premature mortality from cardiovascular diseases in Hungary and the European Union, 1970–1997. (In Hungarian). Orv. Hetil., 2000, 41 , 601–607.

    Ádány R. , 'Trends of premature mortality from cardiovascular diseases in Hungary and the European Union, 1970–1997 (In Hungarian) ' (2000 ) 41 Orv. Hetil. : 601 -607 .

    • Search Google Scholar
  • Szanto, Z., Susansky, E., Kopp, M.: Relationships between unfavourable health status and smoking cessation attempts in Hungary. Soz. Praventivmed., 2005, 50 , 324–333.

    Kopp M. , 'Relationships between unfavourable health status and smoking cessation attempts in Hungary ' (2005 ) 50 Soz. Praventivmed. : 324 -333 .

    • Search Google Scholar
  • Wood, D. A.: Euro Heart Survey Programme. The EUROASPIRE surveys: time trends in lifestyle, risk factor and therapeutic management of coronary patients 1995–2007. Presented at the European Society of Cardiology (ESC) Congress, Vienna, Austria, September 1–5, 2007.

  • EUROASPIRE I and II Group: Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet, 2001, 357 , 995–1001.

    'Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events ' (2001 ) 357 Lancet : 995 -1001 .

    • Search Google Scholar
  • Ministry of Health, Hungary (Budapest): Johan Béla National Programme for the Decade of Health. 2003. Available at: http://www.eum.hu/index.php?akt_menu=3538 . Cited 12 June 2007

  • EUROASPIRE Study Group: EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur. Heart J., 1997, 18 , 1569–1582.

    'EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events ' (1997 ) 18 Eur. Heart J. : 1569 -1582 .

    • Search Google Scholar
  • EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countrie. principal results from EUROASPIRE II Euro Heart Survey Programme.; Eur. Heart J., 2001, 22 , 554–572.

    'Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countrie ' (2001 ) 22 principal results from EUROASPIRE II Euro Heart Survey Programme.; Eur. Heart J. : 554 -572 .

    • Search Google Scholar
  • Paragh, G., Márk, L., Zámolyi, K. et al.: Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Clin. Drug Invest., 2007, 27 , 647–660.

    Zámolyi K. , 'Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study ' (2007 ) 27 Clin. Drug Invest. : 647 -660 .

    • Search Google Scholar
  • Van Ganse, E., Laforest, L., Alemao, E. et al.: Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr. Med. Res. Opin., 2005, 21 , 1389–1399.

    Alemao E. , 'Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study ' (2005 ) 21 Curr. Med. Res. Opin. : 1389 -1399 .

    • Search Google Scholar
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285 , 2486–2497.

    'Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) ' (2001 ) 285 JAMA : 2486 -2497 .

    • Search Google Scholar
  • De Backer, G., Ambrosioni, E., Borch-Johnsen, K. et al.: European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention and clinical practice. Eur. J. Cardiovasc. Prev. Rehabil., 2003, 10 (Suppl. 1) , S1–10.

    Borch-Johnsen K. , 'European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention and clinical practice ' (2003 ) 10 Eur. J. Cardiovasc. Prev. Rehabil. : S1 -10 .

    • Search Google Scholar
  • Maron, D. J., Fazio, S., Linton, M. F.: Current perspectives on statins. Circulation, 2000, 101 , 207–213.

    Linton M. F. , 'Current perspectives on statins ' (2000 ) 101 Circulation : 207 -213 .

  • Roberts, W. C.: The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am. J. Cardiol., 1997, 80 , 106–107.

    Roberts W. C. , 'The rule of 5 and the rule of 7 in lipid-lowering by statin drugs ' (1997 ) 80 Am. J. Cardiol. : 106 -107 .

    • Search Google Scholar
  • Jacobson, T. A., Gutkin, S. W., Harper, C. R.: Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. Curr. Med. Res. Opin., 2006, 22 , 1065–1073.

    Harper C. R. , 'Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study ' (2006 ) 22 Curr. Med. Res. Opin. : 1065 -1073 .

    • Search Google Scholar
  • Alemao, E., Yin, D., Sintonen, H. et al.: Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the national FINRISK study. Am. J. Cardiovasc. Drugs, 2006, 6 , 349–355.

    Sintonen H. , 'Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the national FINRISK study ' (2006 ) 6 Am. J. Cardiovasc. Drugs : 349 -355 .

    • Search Google Scholar
  • Pearson, T. A., Laurora, I., Chu, H. et al.: The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med., 2000, 160 , 459–467.

    Chu H. , 'The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals ' (2000 ) 160 Arch. Intern. Med. : 459 -467 .

    • Search Google Scholar
  • Banegas, J. R., Vegazo, O., Serrano, P. et al.: HISPALIPID Study Group Investigators. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis, 2006, 188 , 420–424.

    Serrano P. , 'HISPALIPID Study Group Investigators. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain ' (2006 ) 188 Atherosclerosis : 420 -424 .

    • Search Google Scholar
  • Assmann, G., Benecke, H., Neiss, A. et al.: Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians’ Experience and Evaluation). Eur. J. Cardiovasc. Prev. Rehabil., 2006, 13 , 776–783.

    Neiss A. , 'Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians’ Experience and Evaluation) ' (2006 ) 13 Eur. J. Cardiovasc. Prev. Rehabil. : 776 -783 .

    • Search Google Scholar
  • Ho, K-T., Chin, K-W., Ng, K-S. et al.: The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am. J. Cardiovasc. Drugs, 2006, 6 , 383–391.

    Ng K-S. , 'The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease ' (2006 ) 6 Am. J. Cardiovasc. Drugs : 383 -391 .

    • Search Google Scholar
  • Ose, L., Skjeldestad, F. E., Bakken, I. J. et al.: Lipid management and cholesterol goal attainment in Norway. Am. J. Cardiovasc. Drugs, 2006, 6 , 121–128.

    Bakken I. J. , 'Lipid management and cholesterol goal attainment in Norway ' (2006 ) 6 Am. J. Cardiovasc. Drugs : 121 -128 .

    • Search Google Scholar
  • García Ruiz, F. J., Marín Ibáñez, A., Pérez-Jiménez, F. et al.: REALITY Study Group. Current lipid management and low cholesterol goal attainment in common daily practice in Spain: the REALITY Study. Pharmacoeconomics, 2004, 22 (Suppl. 3) , 1–12.

    Pérez-Jiménez F. , 'REALITY Study Group. Current lipid management and low cholesterol goal attainment in common daily practice in Spain: the REALITY Study ' (2004 ) 22 Pharmacoeconomics : 1 -12 .

    • Search Google Scholar
  • Ballantyne, C. M., Blazing, M. A., King, T. R. et al.: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol., 2004, 93 , 1487–1494.

    King T. R. , 'Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia ' (2004 ) 93 Am. J. Cardiol. : 1487 -1494 .

    • Search Google Scholar
  • Stein, E., Stender, S., Mata, P. et al.: Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J., 2004, 148 , 447–455.

    Mata P. , 'Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin ' (2004 ) 148 Am. Heart J. : 447 -455 .

    • Search Google Scholar
  • Ballantyne, C. M., Abate, N., Yuan, Z. et al.: Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J., 2005, 149 , 464–473.

    Yuan Z. , 'Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study ' (2005 ) 149 Am. Heart J. : 464 -473 .

    • Search Google Scholar
  • Catapano, A. L., Davidson, M. H., Ballantyne, C. M. et al.: Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemia patients. Curr. Med. Res. Opin., 2006, 22 , 2041–2053.

    Ballantyne C. M. , 'Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemia patients ' (2006 ) 22 Curr. Med. Res. Opin. : 2041 -2053 .

    • Search Google Scholar
  • Goldberg, R. B., Guyton, J. R., Mazzone, T. et al.: Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin. Proc., 2006, 81 , 1579–1588.

    Mazzone T. , 'Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study ' (2006 ) 81 Mayo Clin. Proc. : 1579 -1588 .

    • Search Google Scholar
  • Ballantyne, C. M., Weiss, R., Moccetti, T. et al.: EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am. J. Cardiol., 2007, 99 , 673–680.

    Moccetti T. , 'EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study) ' (2007 ) 99 Am. J. Cardiol. : 673 -680 .

    • Search Google Scholar
  • Blagden, M. D., Chipperfield, R.: Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr. Med. Res. Opin., 2007, 23 , 767–775.

    Chipperfield R. , 'Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease ' (2007 ) 23 Curr. Med. Res. Opin. : 767 -775 .

    • Search Google Scholar
  • Gazi, I. F., Daskalopoulou, S. S., Nair, D. R. et al.: Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr. Med. Res. Opin., 2007, 23 , 2183–2192.

    Nair D. R. , 'Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin ' (2007 ) 23 Curr. Med. Res. Opin. : 2183 -2192 .

    • Search Google Scholar
  • Kashyap, M. L., McGovern, M. E., Berra, K. et al.: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol., 2002, 89 , 672–678.

    Berra K. , 'Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia ' (2002 ) 89 Am. J. Cardiol. : 672 -678 .

    • Search Google Scholar
  • Lindgren, P., Borgström, F., Stålhammar, J. et al.: Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolemia not at consensus goal after 3 months of treatment with lipid-lowering drugs. Int. J. Clin. Pract., 2007, 61 , 1410–1414.

    Stålhammar J. , 'Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolemia not at consensus goal after 3 months of treatment with lipid-lowering drugs ' (2007 ) 61 Int. J. Clin. Pract. : 1410 -1414 .

    • Search Google Scholar
  • Lee, J. K., Grace, K. A., Taylor, A. J.: Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA, 2006, 296 , 2563–2571.

    Taylor A. J. , 'Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial ' (2006 ) 296 JAMA : 2563 -2571 .

    • Search Google Scholar
  • Erkkilä, A. T., Sarkkinen, E. S., Koukkunen, H. et al.: Concordance of diet with the recommended cholesterol lowering diet in patients with coronary heart disease. Eur. J. Clin. Nutr., 1998, 52 , 279–285.

    Koukkunen H. , 'Concordance of diet with the recommended cholesterol lowering diet in patients with coronary heart disease ' (1998 ) 52 Eur. J. Clin. Nutr. : 279 -285 .

    • Search Google Scholar
  • Pados, G., Karádi, I., Paragh, G. et al.: New features in the recommendations of the Second Hungarian Therapeutic Consensus Conference. (In Hungarian). Orv. Hetil., 2006, 147 , 1299–1306.

    Paragh G. , 'New features in the recommendations of the Second Hungarian Therapeutic Consensus Conference (In Hungarian) ' (2006 ) 147 Orv. Hetil. : 1299 -1306 .

    • Search Google Scholar
  • Graham, I., Atar, D., Borch-Johnsen, K. et al.: European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prevent. Rehab., 2007, 14 (Suppl. 2) , S1–113.

    Borch-Johnsen K. , 'European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) ' (2007 ) 14 Eur. J. Cardiovasc. Prevent. Rehab. : S1 -113 .

    • Search Google Scholar
  • Collapse
  • Expand

Hungarian Medical Journal
Language English
Size  
Year of
Foundation
2007
Publication
Programme
ceased
Volumes
per Year
 
Issues
per Year
 
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1788-6139 (Print)
ISSN 1789-0403 (Online)